Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 (ZnCOVID-19)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04551339 |
Recruitment Status :
Completed
First Posted : September 16, 2020
Last Update Posted : August 10, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Healthy Health Care Worker Patient Transmission Aging | Dietary Supplement: PreserVision AREDS formulation soft gels or tablets Dietary Supplement: Multivitamin with 11mg of zinc | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 2700 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Other |
Official Title: | Zinc Versus Multivitamin Micronutrient Supplementation to Support Immune Health in the Setting of COVID-19 Pandemic: A Randomized Study |
Actual Study Start Date : | September 28, 2020 |
Actual Primary Completion Date : | May 28, 2021 |
Actual Study Completion Date : | May 28, 2021 |

Arm | Intervention/treatment |
---|---|
Active Comparator: High dose Zinc (PreserVision AREDS formulation soft gels or tablets)
Subjects will have a high dose Zinc supplementation in combination with Copper, Vitamin C/E and beta-carotene
|
Dietary Supplement: PreserVision AREDS formulation soft gels or tablets
Two tabs taken daily for three months |
Active Comparator: Multivitamin with 11mg of zinc
Subjects in this arm will have a multivitamin supplement with 11mg of zinc
|
Dietary Supplement: Multivitamin with 11mg of zinc
One tab taken daily for three months |
- COVID-19 illness requiring hospitalization [ Time Frame: Through study completion, approximately 3 months ]Total number of subjects admitted to the hospital in relations to COVID-19 illness PCR or undergo seroconversion
- Illness without hospitalization [ Time Frame: Through study completion, approximately 3 months ]Total number of subjects with COVID-19 illness that are not hospitalized
- Supplemental oxygen therapy during hospitalization [ Time Frame: Through study completion, approximately 3 months ]Total number of subjects to require supplemental oxygen therapy during hospitalization for COVID-19
- Invasive ventilation during hospitalization [ Time Frame: Through study completion, approximately 3 months ]Total number of subjects to require invasive ventilation during hospitalization for COVID-19
- Mortality [ Time Frame: Through study completion, approximately 3 months ]Total number of subject deaths

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 90 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Age ≥50 years old OR primary healthcare professional (defined as having a job that has had direct patient contact during the COVID-19 pandemic) and ≥18 years old
- No symptoms of COVID-19 (a fever of 100.0o F or greater, OR a new cough, OR new shortness of breath, OR new sore throat, OR new diarrhea, OR new fast breathing (respiratory distress), OR new chills, OR new muscle aches (myalgias), OR new loss of smell, OR new change or loss of taste sensation) in the past 7 days
- Have a negative Elecsys Anti-SARS-CoV-2 immunoassay antibody test at screening
- Have not had close contact with a person with a LABORATORY CONFIRMED case of COVID-19 without full PPE (Close contact is defined by CDC as: Being within approximately 6 feet of a COVID-19 patient for a total of 15 minutes or more over a 24 hour period) or having direct contact with infectious secretions of a COVID-19 patient (e.g. being coughed on)) in the last 14 days
- Mayo Clinic patient who has a patient online account set up or is willing to set up an online account
- Must have a valid email address and internet service
Exclusion Criteria:
- History of positive or indeterminate COVID PCR test prior to screening or Elecsys Anti-SARS-CoV-2 immunoassay antibody test positive or indeterminate at screening
- Active symptoms of COVID ((a fever of 100.0o F or greater, OR a new cough, OR new shortness of breath, OR new sore throat, OR new diarrhea, OR new fast breathing (respiratory distress), OR new chills, OR new muscle aches (myalgias), OR new loss of smell, OR new change or loss of taste sensation)) in past 7 days
- Known intolerance to multivitamins or zinc supplements from prior exposure
- Inability to complete follow-up questions or grant access to electronic health record for surveillance
- Have had close contact with a person with a LABORATORY CONFIRMED case of COVID-19 in past 14 days
- Current or former smoker less than 5 years ago
- Pregnant or breastfeeding
- Prisoner
-
Any subject with known immunosuppressed state, including
- A history of solid organ or bone marrow transplantation
- Subjects currently receiving chemotherapy
- Current rheumatologic or autoimmune illness requiring treatment with glucocorticoids, antimetabolite agents (methotrexate, azathioprine, mercaptopurine, fluorouracil, mycophenolate, leflunomide), IMIDs (lenalidomide, thalidomide, pomalidomide), calcineurin inhibitors (tacrolimus, cyclosporine), mTOR inhibitors (sirolimus, everolimus), or any monoclonal antibody drugs (including any drug given intravenously or subcutaneously) for the purpose of immunosuppression
- Subjects with HIV or primary immunodeficiency syndromes

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04551339
United States, Arizona | |
Mayo Clinic in Scottsdale | |
Scottsdale, Arizona, United States, 85259 | |
United States, Florida | |
Mayo Clinic in Jacksonville | |
Jacksonville, Florida, United States, 32224 | |
United States, Minnesota | |
Mayo Clinic in Rochester | |
Rochester, Minnesota, United States, 55905 |
Principal Investigator: | Atta Behfar, MD, PhD | Mayo Clinic | |
Principal Investigator: | Albert Hakaim, MD | Mayo Clinic | |
Principal Investigator: | Ayan Sen, MD | Mayo Clinic |
Responsible Party: | Atta Behfar, Principal Investigator, Mayo Clinic |
ClinicalTrials.gov Identifier: | NCT04551339 |
Other Study ID Numbers: |
20-004637 |
First Posted: | September 16, 2020 Key Record Dates |
Last Update Posted: | August 10, 2021 |
Last Verified: | August 2021 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Zinc Immune health |